Outsourcing-Pharma.com compiles the news that has featured in the
clinical contract community of late, involving Global Research
Services, Quintiles and Icon.
Pharmaceutical Products Development (PPD) has announced it is
moving into Russia, along with the news of positive trial results
for its statin, although profits dipped again during the fourth
quarter of 2007 as its R&D bill mounts.
MDS Pharma Services is the latest contract research organisation
(CRO) to branch out into a new and exotic emerging market location,
with the establishment of an office in Sao Paulo, Brazil.
Pharmaceutical Product Development (PPD) has initiated central
laboratory services in China in response to the country's budding
clinical trials scene.
Eli Lilly has released a statement strongly objecting to
implications made in a New York Times article that it has
suppressed results of negative clinical trials.
Dublin-based contract research organisation (CRO) Icon Clinical
Research has forayed further into Eastern Europe with the opening
of three new offices there.
Pfizer is vowing to fight on as Nigerian court battles against its
subsidiary in the country wage on over its alleged involvement in
child deaths through experimentation over a decade ago.
Outsourcing-Pharma.com compiles the news that has featured in the
clinical contract community of late, involving Encorium Group,
Holmes Biopharma and Novotech.
One Equity Partners (OEP), the private equity arm of JPMorgan
Chase, is in the process of selling its stake in Quintiles for a
reported sum of over $3bn.
Outsourcing-Pharma.com compiles the news that has featured in the
clinical contract community of late, involving PPD, PRA, Accutest
and Premier Research.
MDS Pharma is continuing its efforts to move on from the trouble
caused in its Pharma Services segment by a US Food and Drug
Administration (FDA) review of its Montreal-area bioanalytical
facilities.
Two French contract research organisations (CROs) that specialise
in ophthalmology have banded together to offer specialised services
to this niche market.
US researchers have developed a fast and inexpensive protein
biomarker detection device that could simplify disease diagnosis
and aid in following disease progression in drug trials.
Eisai is planning to step up its clinical research presence in Asia
and has chosen Singapore as a hub from which to coordinate its
research activities.
As eClinical gathers momentum, Outsourcing-Pharma.com spoke to two
contract research organisations (CROs), Icon and Parexel, to get
their views on the present and future of these emerging
technologies.
New research from Frost & Sullivan provides a snapshot of
biopharma spending trends on contract research organisations
(CROs), along with forecasts for industry growth.
Management of publicly-traded Synexus have agreed to the £18.1m
(€25.7m) sale of the company to a private equity firm that has
promised to fund its global expansion ventures.
This week two sets of contract research organisations (CROs) have
announced plans to link arms in order to spread their reach further
into this increasingly globalised marketplace.
PPD's decision to in-license an investigational compound is proving
to be a drag on its bottom line as the firm continues to seek a
development partner for the drug.
The US Food and Drug Administration (FDA) has slammed
Sanofi-Aventis over its failure to act on known instances of fraud
during clinical trials of its antibiotic Ketek (telithromycin) -
accusations that the firm continues to deny.
Two major bioscience industry trade associations have called for
changes to be made to the European clinical trials directive in
order to bring about "harmonisation, transparency and consistency"
in this area across the...
Parexel has purchased a clinical research organisation (CRO) in
Taiwan as a means to exert its presence in this industry's budding
Asia-Pacific region.
While contract research organisations (CROs) now dominate the
clinical trials market, questions are being raised about the risks
of 'commercialising' clinical studies, according to new research.
The US Food and Drug Administration (FDA) has been called into
question again after the release of a damning report, this time
suggesting the agency is inadequate in its safety monitoring of
clinical trials.
Pfizer will appear this week in a Nigerian court to face
allegations that it caused the death of Nigerian children over a
decade ago when it conducted a clinical trial of its
meningitis drug Trovan (trovafloxacin) in the country.
Californian marketing company BlueLithium has launched a new
web-based solution to help pharma companies overcome the challenges
of recruiting patients for clinical trials.
Pfizer is considering offers from investors in a bid to spin off
its drug research and development laboratory in Japan and make it
an independent entity, according to media reports.
Averion has formed a new partnership in South America's clinical
trial hotspot Brazil - as it continues to tip-toe beyond North
America and Europe into emerging markets.
Two North American contract research organisation (CROs) have this
week announced acquisitive moves into emerging clinical trials
markets, while a third firm has extended an Asian partnership, as
the emerging market migration continues.
'Legislative chaos' has been preventing Poland from reaching its
full potential in the increasingly competitive central Eastern
European (CEE) region, although progress is being made.
etrials and Clinphone, two big players in the eclinical industry
are struggling to keep their heads above water as both companies'
recent woes have impacted their bottom line.
Russian contract research organisation (CRO) Synergy Research Group
has hooked up with a US-based CRO in a bid to expand its services
to North America.
Pfizer, among others, recently offered an insight into R&D
outsourcing in Japan, where this services market is still fairly
immature, with growth potential in several key areas.
Outsourcing-Pharma.com compiles the news that featured in the
clinical contract community this past week, involving Innovaderm
Research, Target Health, Qualia Clinical Service, and Quintiles.
PharmaNet has reported second quarter results that place it back in
the red after it had only just clawed its way back into the black
in the first quarter, following a string of quarterly losses.